Randomized Phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder

Urology

Volumn 66, Issue 3, 2005, Pages 527-530

  Gårdmark, Truls ^a   Carringer, Malcolm ^b   Beckman, Eva ^b   Malmström, Per Uno ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GEMCITABINE; SODIUM CHLORIDE; SPASMOLYTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; BLADDER CANCER; BLOOD TOXICITY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; DRUG EFFECT; DRUG SAFETY; FEMALE; FEVER; HUMAN; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; UROGENITAL TRACT CANCER;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; URINARY BLADDER NEOPLASMS;

EID: 24144443874     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2005.03.084     Document Type: Article

References (12)

1. R.J. Sylvester, A.P. van der Meijden, D.L. Lamm Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
2. M.D. Shelley, T.J. Wilt, J. Court Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer a meta-analysis of randomized trials BJU Int 93 2004 485 490
3. P. Nygren, K. Csoka, R. Larsson Activity of standard and investigational cytotoxic drugs in primary cultures of tumor cells from patients with kidney and urinary bladder carcinomas J Urol 162 1999 2200 2204
4. L.W. Hertel, G.B. Boder, J.S. Kroin Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) Cancer Res 50 1990 4417 4422
5. M.S. Aapro, C. Martin, S. Hatty Gemcitabine-a safety review Anticancer Drugs 9 1998 191 201
6. G. Dalbagni, P. Russo, J. Sheinfeld Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder J Clin Oncol 20 2002 3193 3198
7. A.P. van der Meijden, R.R. Hall, K.H. Kurth Phase II trials in Ta, T1 bladder cancer the marker tumour concept Br J Urol 77 1996 634 637
8. E. De Berardinis, G. Antonini, G.J. Peters Intravesical administration of gemcitabine in superficial bladder cancer a phase I study with pharmacodynamic evaluation BJU Int 93 2004 491 494
9. P. Gontero, G. Casetta, G. Maso Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC) Eur Urol 46 2004 339 343
10. M. Laufer, S. Ramalingam, M.P. Schoenberg Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder a phase I and pharmacokinetic study J Clin Oncol 21 2003 697 703
11. J. Palou, A. Carcas, J. Segarra Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer J Urol 172 2004 485 488
12. J.A. Witjes, A.G. van der Heijden, J.L. Vriesema Intravesical gemcitabine a phase 1 and pharmacokinetic study Eur Urol 45 2004 182 186